Clindamycin

Clindamycin

• CAS Number: 18323-44-9
• UNSPSC Description: Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].
• Target Antigen: Antibiotic; Bacterial; Parasite
• Type: Reference compound
• Related Pathways: Anti-infection
• Applications: COVID-19-immunoregulation
• Field of Research: Infection; Cancer
• Assay Protocol: https://www.medchemexpress.com/clindamycin.html
• Purity: 99.90
• Solubility: DMSO : 125 mg/mL (ultrasonic)
• Smiles: CN(C[C@H](CCC)C1)[C@@H]1C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O
• Molecular Weight: 424.98
• References & Citations: [1]Hodille E, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2018 Oct 20;17(1):38.|[2]Kremsner PG. Clindamycin in malaria treatment. J Antimicrob Chemother. 1990 Jan;25(1):9-14.|[3]Kishi K, et al. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. Antimicrob Agents Chemother. 1999 Mar;43(3):616-22.|[4]Veringa EM, et al. Clindamycin at subinhibitory concentrations enhances antibody- and complement-dependent phagocytosis by human polymorphonuclear leukocytes of Staphylococcus aureus. Chemotherapy. 1987;33(4):243-9. |[5]Naal FD, et al. The effects of clindamycin on human osteoblasts in vitro. Arch Orthop Trauma Surg. 2008 Mar;128(3):317-23.|[6]Faggion PI, et al. Is the penetration of clindamycin into the masseter muscle really enough to treat odontogenic infections? Clin Oral Investig. 2021 May;25(5):3257-3266. |[7]Yang SH, Lee MG. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability. Int J Pharm. 2007 Mar 6;332(1-2):17-23.|[8]Hirata N, et al. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother. 2001 Sep;45(9):2638-42. ACS Omega. March 3, 2022.|Acta Pharm Sin B. 2021 Mar 11.|Dermatol Clin. 2024 September 12.|EBioMedicine. 2022 Apr;78:103943.|Water Res. 2023 May 21, 120110.|bioRxiv. 2024 Jan 18.|bioRxiv. 2024 May 10.|EBioMedicine. 2022 Apr;78:103943.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, protect from light)
• Clinical Information: Launched